CJC-1295 (No DAC), identical to Modified GRF (1-29), is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). Unlike the long-acting DAC version, it lacks the albumin-binding Drug Affinity Complex, so it does not tether to serum albumin and is therefore short-acting, with a reported plasma half-life of approximately 30 minutes. This page summarizes the preclinical and clinical literature for research use only.
Scientific Background
CJC-1295 (No DAC) acts as an agonist at the pituitary GHRH receptor (GHRH-R), a class-B seven-transmembrane G-protein-coupled receptor on anterior-pituitary somatotrophs. Binding couples predominantly to Gs and adenylyl cyclase, raising intracellular cAMP, activating PKA, driving CREB phosphorylation and voltage-dependent calcium influx, and triggering exocytosis of stored growth hormone (GH); chronically it also supports Pit-1-mediated GH gene transcription (Mayo 1995). Downstream, pituitary GH release raises hepatic IGF-1.
- The N-terminal 1-29 fragment of human GHRH, the same active core as Sermorelin, carrying four stabilizing substitutions (position 2 D-Ala, 8 Gln, 15 Ala, 27 Leu) documented for the tetrasubstituted core in Jetté 2005.
- The substitutions confer resistance to dipeptidyl-peptidase-IV (DPP-IV) cleavage, raising potency and metabolic stability versus native GRF(1-29).
- The isolated D-Ala2 substitution lowered metabolic clearance from 39.7 to 21 mL/kg/min and lengthened IV disappearance half-time from 4.3 to 6.7 minutes in humans (Soule 1994).
- Short-acting clearance produces a pulsatile GH profile, contrasting with the sustained albumin-bound stimulation of the DAC version (~5.8-8.1 days; Teichman 2006).
Composition / Biochemical Properties
Supplied as a lyophilized peptide. The figures below reflect vendor and chemical-supplier data (not peer-reviewed) and should be treated as approximate.
- Sequence (N to C): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2.
- Reported molecular formula C152H252N44O42; molar mass approximately 3367.9 g/mol. CAS 446036-97-1 is sometimes applied to the CJC-1295/DAC family.
- Short-acting: reported plasma half-life approximately 30 minutes (commonly cited range ~30 minutes to ~2 hours), versus native Sermorelin/GRF(1-29) at roughly 6-7 minutes (IV) to ~10-20 minutes.
Buy CJC-1295 (No DAC) at Bergdorf Bioscience
Bergdorf Bioscience offers CJC-1295 (No DAC) as a single lyophilized vial for laboratory and research applications.
- 1 Pack: single 2mg lyophilized vial (2mg per vial).
Each batch is HPLC-tested to confirm a purity of at least 99%, and a Certificate of Analysis (CoA) documents identity, purity, and quality-control results so researchers can verify exactly what they receive.
Worldwide Shipping - Safe and Hassle-Free
We ship CJC-1295 (No DAC) worldwide with discreet, protective packaging designed to maintain the integrity of the lyophilized peptide in transit. Orders are processed promptly with reliable tracking, so your research material arrives safely and without hassle.
GHRH receptor agonist; stimulates pituitary somatotrophs to release GH in pulsatile pattern.
Note: The dosages listed correspond to typical ranges from published research literature. They do not replace advice from a qualified researcher or physician.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.43% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.